EC approves Lundbeck's Brintellix for MDD

The European Commission approved an MAA from H. Lundbeck A/S (CSE:LUN) for Brintellix vortioxetine to treat major depressive disorder (MDD) in adults. Lundbeck plans to launch the serotonin modulator ...